Vaxart (VXRT) Jumped Recently, But Pulled Back Quickly: But Why?
The coronavirus pandemic has been one of history’s deadliest crises to have hit the world and naturally, the market for its vaccines has become the hotbed for investors.
Over the past year or so, many companies have come up with their own vaccines and have rewarded investors handsomely. However, one of the companies that could change the game with regards to coronavirus vaccines altogether is Vaxart (NASDAQ:VXRT). The company has come up with a COVID 19 pill that could prove to be an alternative to often inconvenient vaccine injections. The stock is still quite far away from its peak levels and hence, it might be a good move for investors to start tracking Vaxart.
However, there is still a long way to go before one should get excited about the COVID 19 vaccine pill from Vaxart. Investors need to note that the stock can move dramatically as can be evidenced from its price range of $2.23 to $24.90 in the past 52 weeks. Currently, the stock is trading below $7 a share and hence, it is nearer to its bottom. That might be the ideal opportunity for many investors to get hold of the Vaxart stock. At the end of the day, the possibility of the COVID 19 vaccine pill could result in a transformative change in the industry and lead to significant growth for the company.
The company has managed to complete the Phase 1 study into its vaccine VXA Cov2-1 so far and if Vaxart does manage to get the approval from regulators, then it could be a massive deal. Millions of Americans are yet to be completely vaccinated and a vaccine pill is expected to make the entire process much easier. Additionally, it is going to be quicker as well. The company is looking to make considerable progress in this particular front and it might just be the right time to start tracking Vaxart.
CytoDyn (CYDY) Stock Extends Fall: Fall Another 10%
For the past couple of years, biotech firm CytoDyn (OTCMKTS:CYDY) has come into prominence due to its work with leronlimab, which is known to work against a range of conditions.
On Wednesday, the CytoDyn stock was in action but it actually recoded a decline of as much as 10%. There was no new about the company yesterday that could have led to the decline. However, in this sort of a situation, it could be a good idea to take a look at some recent development. Back on May 6, the company announced that it was on the verge of starting the trial of leronlimab in patients who were suffering from severe symptoms of COVID 19.
The trial is going to be conducted in collaboration with the academic research organisation Albert Einstein Israelite Hospital (AEIH). The trials are going to be conducted at as many as 45 clinical sites all across the United States. In this regard, it is necessary to note that the Phase III trials are expected to deliver the data that is going to be required by ANVISA, the regulatory body in Brazil, for approving leronlimab for the treatment of COVID 19 infected patients in the country.
It was also announced that CytoDyn is looking to have an interim analysis of the data through October and November. The trial is going to enroll 120 patients suffering from critical symptoms of COVID 19. Last month, the company had announced that it signed an exclusive supply and distribution agreement with Chiral Pharma Corporation. By way of this agreement, CytoDyn is going to supply Chiral with as many as 200000 vials of leronlimab that are going to be administered to critically ill COVID 19 patients in Philippines. These are all important developments and despite the fall in the CytoDyn stock yesterday, investors could consider tracking the stock.